We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
-16.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.14B
AUM Growth
-$212M
(-16%)
Cap. Flow
+$85.4M
Cap. Flow
% of AUM
7.49%
Top 10 Holdings %
Top 10 Hldgs %
46.56%
Holding
206
New
51
Increased
51
Reduced
18
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$27.8M |
| 2 |
Humana
HUM
|
+$19.1M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$15.3M |
| 4 |
QTNT
Quotient Limited Ordinary Shares
QTNT
|
+$13.2M |
| 5 |
MDVN
MEDIVATION, INC.
MDVN
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DYAX
DYAX CORPORATION
DYAX
|
+$68.4M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$12.9M |
| 3 |
Baxter International
BAX
|
+$10.1M |
| 4 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$8.54M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.87% |
| 2 | Consumer Staples | 0.6% |
| 3 | Consumer Discretionary | 0.11% |
| 4 | Industrials | 0.04% |
| 5 | Financials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABMD
101
DELISTED
Abiomed Inc
ABMD
| $920K | 0.08% |
+9,700
| New | +$819K |
|
102
Indaptus Therapeutics
INDP
$147M
| $795K | 0.07% |
86
-37
| -30% | -$344K |
|
|
CGNT
103
DELISTED
Cogentix Medical, Inc.
CGNT
| $741K | 0.07% |
673,257
| – | – |
|
104
SCYNEXIS
SCYX
$54M
| $705K | 0.06% |
2,188
| – | – |
|
105
Vanda Pharmaceuticals
VNDA
$322M
| $601K | 0.05% |
71,849
| – | – |
|
|
MGLN
106
DELISTED
Magellan Health Services, Inc.
MGLN
| $596K | 0.05% |
8,772
+5,421
| +162% | +$326K |
|
107
AMN Healthcare
AMN
$1.3B
| $586K | 0.05% |
+17,428
| New | +$498K |
|
108
Icon
ICLR
$12.9B
| $570K | 0.05% |
7,585
+5,372
| +243% | +$376K |
|
109
HCA Healthcare
HCA
$92.3B
| $561K | 0.05% |
+7,186
| New | +$502K |
|
110
UnitedHealth
UNH
$361B
| $560K | 0.05% |
4,346
+2,706
| +165% | +$320K |
|
111
Gilead Sciences
GILD
$184B
| $553K | 0.05% |
6,024
+3,567
| +145% | +$322K |
|
|
INFI
112
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $527K | 0.05% |
100,000
+80,000
| +400% | +$490K |
|
113
Neurogene
NGNE
$806M
| $526K | 0.05% |
2,980
| – | – |
|
114
Elevance Health
ELV
$87.5B
| $521K | 0.05% |
+3,747
| New | +$501K |
|
|
ALPN
115
DELISTED
Alpine Immune Sciences Inc
ALPN
| $521K | 0.05% |
31,250
| – | – |
|
116
Molina Healthcare
MOH
$10.7B
| $519K | 0.05% |
8,052
+5,252
| +188% | +$312K |
|
117
Enanta Pharmaceuticals
ENTA
$419M
| $514K | 0.05% |
+17,507
| New | +$487K |
|
|
HOLX
118
DELISTED
Hologic
HOLX
| $508K | 0.04% |
+14,732
| New | +$514K |
|
|
AMED
119
DELISTED
Amedisys
AMED
| $507K | 0.04% |
10,493
+5,845
| +126% | +$226K |
|
|
WCG
120
DELISTED
Wellcare Health Plans, Inc.
WCG
| $505K | 0.04% |
+5,448
| New | +$452K |
|
|
VWR
121
DELISTED
VWR Corporation
VWR
| $505K | 0.04% |
+18,657
| New | +$461K |
|
|
PRAH
122
DELISTED
PRA Health Sciences, Inc.
PRAH
| $502K | 0.04% |
+11,751
| New | +$497K |
|
123
McKesson
MCK
$105B
| $501K | 0.04% |
3,188
+2,009
| +170% | +$325K |
|
124
Stellantis
STLA
$19.6B
| $500K | 0.04% |
62,559
-32,531
| -34% | -$235K |
|
125
Universal Health Services
UHS
$10.5B
| $498K | 0.04% |
+3,989
| New | +$449K |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
LSERS
CAG
MCM
Perceptive Advisors's Q1 2016 Portfolio in Review
As of Q1 2016, Perceptive Advisors held 206 positions worth $1.14B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Perceptive Advisors deployed $85.4M of net new capital in Q1 2016, opening 51 new positions and adding to 51 existing holdings. Its largest new stake was Humana: 110,000 shares worth $20.1M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $12.9M trimmed.
- Perceptive Advisors's largest Q1 2016 buy was Humana: 110,000 shares worth $20.1M.
- Perceptive Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $27.8M increase.
- Perceptive Advisors's biggest Q1 2016 reduction was Teva Pharmaceuticals, cutting an estimated $12.9M.
- Perceptive Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $68.4M.
- Perceptive Advisors's ten largest holdings make up 47% of its $1.14B portfolio in Q1 2016.
- Perceptive Advisors opened 51 new positions and closed 36 in Q1 2016.
- Perceptive Advisors's portfolio value fell 16% quarter-over-quarter to $1.14B.
Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.